U.S. Hematology Update eNewsletter
April 2020

Adverse CV Events Linked to
Non-Hodgkin Lymphoma Treatment?

Medical advances have significantly increased 5-year survival among non-Hodgkin lymphoma patients. According to a recent systematic review and meta-analysis, however, the extent of cardiovascular (CV) adverse effects associated with standard first-line treatments in this patient population is unknown. Read more.


Managing Coagulopathy Associated With COVID-19
While the clinical presentation of COVID-19 is rapidly evolving, manifestations of the disease observed by clinicians in China are consistent with disseminated intravascular coagulopathy and venous thromboembolism. This is thought to be attributable to endothelial dysfunction, which results in a hypercoagulable state. Read more

Follicular Lymphoma Impact on Healthcare Cost and Quality of Life
While the initial management of follicular lymphoma and marginal zone lymphoma is generally successful, these hematological malignancies are associated with high relapse rates. Once initial therapy is no longer effective, subsequent courses include the use of novel agents. However, little is known about the cost-effectiveness of treatment modalities used in the management of these indolent forms of non-Hodgkin’s lymphoma. Read more

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App